我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替格瑞洛和双倍剂量氢氯吡格雷治疗氢氯吡格雷抵抗患者的有效性及安全性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第1期
页码:
86-089
栏目:
临床研究
出版日期:
2016-10-05

文章信息/Info

Title:
Efficacy and safety of ticagrelor and double dosage of clopidogrel in patients with clopidogrel resistance
作者:
张 胜; 孙建辉; 周学中
（常州市第一人民医院心内科，江苏 常州 213003）
Author(s):
ZHANG Sheng;  SUN Jian-hui;  ZHOU Xue-zhong
(Department of Cardiology, Changzhou First People’s Hospital, Changzhou 213003, Jiangsu, China)
关键词:
急性冠脉综合征; 氯吡格雷抵抗; 替格瑞洛; 有效性; 安全性
Keywords:
acute coronary syndrome;  clopidogrel resistance;  ticagrelor;  efficacy;  safety
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨替格瑞洛和双倍剂量氢氯吡格雷在氯吡格雷抵抗的急性冠脉综合征(ACS)患者中的有效性和安全性。方法 选取ACS出现氢氯吡格雷抵抗（血小板抑制率<30%）患者124例，随机分为替格瑞洛组(试药组，63例)，双倍剂量氢氯吡格雷组(对照组，61例)，分别予入院第7天检测血小板抑制率、入院第2天及第7天检测超敏C反应蛋白(hs-CRP),观察1个月及6个月时主要心脏不良事件（MACE）及轻度出血发生率。结果 入院第7天时检测血小板抑制率，两组患者均较前显著升高（P<0.05）；且试药组血小板抑制率高于对照组〔(60±12)% vs.(46±10)%,P<0.05〕。入院第2天检测hs-CRP，两组患者结果无统计学差异〔(19±4) g/L vs.（20±3） g/L〕；第7天时两组患者的hs-CRP均显著降低（P<0.05），且试药组hs-CRP降低更显著〔（6.4±2.1） g/L vs.(10.8±2.8) g/L,P<0.05〕，和对照组相比有统计学差异。随访1个月两组患者之间MACE及轻度出血发生率无显著差异（3% vs. 3%,5% vs. 3%）；随访至6个月时试药组MACE发生率低于对照组（3% vs. 13%,P<0.05），两组之间轻度出血发生率仍旧无明显差异（8% vs. 5%）。结论 ACS出现氢氯吡格雷抵抗患者，选用替格瑞洛具有更好的有效性及安全性。
Abstract:
AIM To investigate the clinical efficacy and safety of ticagrelor and double dosage of clopidogrel in clopidogrel-resistant acute coronary syndrome (ACS) patients. METHODSOne hundred and twenty-four ACS patients with clopidogrel resistance (platelet inhibition rate <30%) were randomly divided into ticagrelor group (group A, n=63) and double dosage of clopidogrel group (group B, n=61). Platelet inhibition rate was tested at the seventh day after admission and high sensitivity C-reactive protein (hs-CRP) was measured at the second day and the seventh day after admission. The incidence rates of major adverse cardiovascular events (MACE) and slight bleeding were compared between groups at the first- and sixth-month follow-up. RESULTSAt the seventh day, platelet inhibition rates in the two groups were significantly elevated (P<0.05) and platelet inhibition in group A was higher than in group B (P<0.05). At the second day, no significant difference in hs-CRP was observed between groups. However, at the seventh day, the hs-CRP in the two groups was significantly reduced (P<0.05) and the hs-CRP in group A was lower than in group B (P<0.05). At the first-month follow-up, there was no significant difference in the incidence rates of MACE and slight bleeding between groups and at the 6-month follow-up, the incidence rate of MACE in group A was significantly lower than in group B (P<0.05), but there was still no significant difference in the incidence rate of slight bleeding between groups. CONCLUSIONTicagrelor is more effective and safer in the treatment of clopidogrel-resistant ACS patients.

参考文献/References

[1]Rioufol G,Finet G,Ginon I,et al.Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study[J].Circulation,2002,106(7):804.
[2]Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J,2012,33(2):2569-2619.
[3]Shim CY,Yoon SJ,Park S,et al.The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation[J].Int J Cardiol,2009,134(3):351-355.
[4]Geisler T,Langer H,Wydymus M,et al.Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation[J].Eur heart J,2006,27(20):2420-2425.
[5]DiNicolantonio JJ,Tomek A.Inactivations,deletions,non-adjudications,and downgrades of clinical endpoints on ticagrelor:serious concerns over the reliability of the PLATO tria[J].Int J Cardio,2013,168(4):4076-4080.
[6]李 靖，王乐丰.急性冠脉综合征抗栓治疗出血情况研究现状[J].国际心血管病杂志,2009,36(5):270.
[7]Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting: response variability,drug resistance, and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
[8]Choi H,Ryu J,Seo H,et al.Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients[J].Int J Chin Pharm,2015,37(5):758-761.
[9]Dridi NP,Johansson PI,Clemmensen P,et al.Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response the TAILOR(Thrombocyt -es And IndividuaLization of Oral antipaltelet therapy in percutaneous coronary intervention)randomized trail[J].Platelets,2014,25(7):506-512.
[10]Lombo B,Diez JG.Ticagrelor:the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes[J].Core Evid,2011,6(1):31-42.
[11]Vivekananthan DP,Bhatt DL,Chew DP,et al.Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention[J].Am J Cardiol,2004,94(3):358-360.
[12]齐 新，刘克强，王 敏,等.冠心病患者血小板聚集功能与炎症因子关系的研究[J].中国循环杂志,2009,24(3):178-181.
[13]Tavassoli N,Voisin S,Carrie D,et al.High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patient[J].Am J Cardiovasc Drugs,2010,10(1):29-35.
[14]Samo? M,Fedor M,Kovár F,et al.Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis[J].Blood Coaqul Fibrinolysis,2016,27(2):117-120.
[15]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
[16]Gurbel PA,Bliden KP,Butler K,et al.Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study[J].Circulation,2010,121(10):1188-1199.

备注/Memo

备注/Memo:
收稿日期：2015-10-14.
作者简介：张胜，主治医师，硕士 Email：zs716715@163.com
更新日期/Last Update: 2016-10-09